Selective Anticancer Effects of Haplophyllum Ptilostylum Extract on SNU-423 Liver Cancer Cells via Mitochondrial Dysfunction and Apoptosis Anticancer effects of H. ptilostylum on SNU-423
Abstract
Hepatocellular carcinoma is one of the most common and lethal cancers worldwide, creating an urgent need for new therapeutic agents. In this context, the present study aimed to investigate the selective anticancer effects of Haplophyllum ptilostylum on SNU-423 liver cancer cells, with a particular focus on mitochondrial dysfunction and apoptosis. Methanolic and dichloromethane extracts of H. ptilostylum were applied to SNU-423 hepatocellular carcinoma cells and HUVEC normal endothelial cells. Cytotoxicity was assessed using the MTT assay. Apoptotic morphology was examined through acridine orange/ethidium bromide staining, while apoptosis was further quantified by Annexin V/PI flow cytometry. Cell cycle distribution was evaluated by flow cytometry, and mitochondrial membrane potential was measured using the JC-1 assay. The extracts significantly reduced cell viability in a dose-dependent manner. JC-1 staining demonstrated mitochondrial membrane depolarization, and AO/EB staining indicated classical apoptotic morphology. Flow cytometry confirmed apoptosis through increased Annexin V-positive cell populations. These findings suggest that H. ptilostylum induces apoptosis in SNU-423 liver cancer cells via mitochondrial dysfunction, positioning it as a noteworthy candidate for further preclinical investigation.
Keywords
Anticancer, Apoptosis, Haplophyllum ptilostylum, Liver cancer, Mitochondria
Supporting Institution
Harran University Scientific Research Projects Coordination Office
Project Number
19063
Ethical Statement
This study was reviewed by the Harran University Faculty of Medicine Ethics Committee (HRÜ/19.06.33, 13.06.2019) and was deemed not to require ethical approval. The research was derived from a master’s thesis submitted to Harran University (Thesis No: 575340, National Thesis Center). In addition, part of this study was presented as an abstract at the 1st International Multidisciplinary Cancer Research Congress, held on September 18–22, 2019.
Thanks
I would like to thank all the authors for their contribu tions.
References
- [1] Clancy E. ACS report shows prostate cancer on the rise, cervical cancer on the decline. Renal & Urology News. 2023; Available at: https://go.gale.com/ps/i.do?id=GALE%7CA738288720&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=15509478&p=HRCA&sw= w&userGroupName=anon%7E7759cb81&aty=open-web-entry (Accessed: 01 December 2025).
- [2] Tyagi IS, Singh R, Pandey A, et al. Non-mitotic proliferation of malignant cancer cells revealed through live-cell imaging of primary and cell-line cultures. Cell Division. 2024;19(1):3.
- [3] Yu X, Zhang Y, Chen L, et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discovery. 2024;10(1):28.
- [4] Qiu S, Li J, Wang Y, et al. Trends in hepatocellular carcinoma mortality rates in the US and projections through 20440. JAMA Network Open. 2024;7(11):e2445525.
- [5] Konyn P, Ahmed A, Kim D. The current trends in the health burden of primary liver cancer across the globe. Clinical and Molecular Hepatology. 2023;29(2):358.
- [6] Krupa K, Ferreira CM, Silva A, et al. Current treatment methods in hepatocellular carcinoma. Cancers. 2024;16(23):4059.
- [7] Farinha D, Sarmento-Ribeiro AB, Faneca H. From conventional therapy to treatment with lipid-polymer hybrid nanoparticles for hepatocellular carcinoma. Materials Today Chemistry. 2025;47:102870.
- [8] Zhonghao J, Fan Y. New advances in the treatment of intermediate and advanced hepatocellular carcinoma. Frontiers in Oncology. 2024;14:1430991.
- [9] Oyebode O, Kandala N, Chilton S, et al. Use of traditional medicine in middle-income countries: a WHO-SAGE study. Health Policy and Planning. 2016;31(8):984–991.
- [10] Mohammadhosseini M, Alilou H, Gholivand K, et al. The genus Haplophyllum Juss.: Phytochemistry and bioactivities—a review. Molecules. 2021;26(15):4664.